# Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

> **NCT07662018** · — · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Prospective Observational Study
- Gemcitabine
- Docetaxel
- Melphalan
- Carboplatin
- Stem Cell Transplantation
- Pediatric Relapsed
- Refractory Germ

## Interventions

- **DRUG:** Gemcitabine (GEM)
- **DRUG:** Docetaxel
- **DRUG:** Melphalan
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT07662018
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-05
- **Primary completion:** 2031-12-31
- **Final completion:** 2033-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662018, "Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07662018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*